Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants

BMJ (Online)

Volumn 340, Issue 7749, 2010, Pages 752-756

  Reid, Steven ^a   Barbui, Cornado ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGGRESSION; AGITATION; AKATHISIA; ANXIETY; AUTOMUTILATION; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG TOLERABILITY; ELECTRIC SHOCK; EVIDENCE BASED MEDICINE; FATIGUE; GENERAL PRACTICE; HEADACHE; HUMAN; HYPONATREMIA; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LONG TERM CARE; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REVIEW; RISK REDUCTION; SEROTONIN UPTAKE; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; VERTIGO;

ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER; FEMALE; HEMORRHAGE; HUMANS; HYPONATREMIA; LONG-TERM CARE; MEDICATION ADHERENCE; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; RISK FACTORS; SELF-INJURIOUS BEHAVIOR; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SUICIDE;

EID: 77950588578     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1468     Document Type: Review

References (36)

1. Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry 2003;5:153-157
2. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-856
3. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009;339:b3999.
4. Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing 2006;35:523-526 (Pubitemid 44295644)
5. ParkerG. Antidepressants on trial: howvalid is the evidence? Br J Psychiatry 2009;194:1-3.
6. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a metaanalysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45. (Pubitemid 351317657)
7. Foumier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
8. Geddes J, Barbui C, Cipriani A. Risk of suicidal behaviour in adults taking antidepressants. BM J 2009;339:b3066.
9. Kupfer DJ, Frank E, Wamhoff J. Mood disorders: update on prevention of recurrence. In: Mundt C, Goldstein MJ, eds. Interpersonal factors in the origin and course of affective disorders. Gaskell/Royal College of Psychiatrists, 1996:289-302.
10. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (update). 2009. (Clinical guideline 90.) http://guidance.nice.org.uk/CG90
11. Anderson IM, Ferner IN, Baldwin RC, Cowen PC, Howard L, Lewis G, et al. Evidence-based guidelines fortreating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacologyguidelines. J Psycftop/iarmacol 2008;22:343-396
12. Spence D. Black dog. BMJ 2009;339:b3995
13. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:65361. (Pubitemid 36246547)
14. Furukawa TA, Cipriani A, Barbui C, Geddes JR. Long-term treatment of depression with antidepressants: a systematic narrative review. Can J Psychiatry 2007;52:545-552 (Pubitemid 47523281)
15. Hansen R, Gaynes B.Thieda P, GartlehnerG, Veaugh-Geiss A, Krebs E, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 2008;59:1121-1130
16. Kaymaz N, van OJ, Loonen AJ, Nolen WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebocontrolled randomized trials. J Clin Psychiatry 2008;69:1423-1436
17. Deshauer D, Moher D, Fergusson D. Impact of study design on the results of continuation studies of antidepressants. J Clin Psychopharmacol 2008;28:467-468
18. Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grimshaw J. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ 2008;178:1293-1301 (Pubitemid 351678352)
19. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CAMJ 2009;180:291-297
20. Stone M, Laughren T, Jones L, Levenson M, Holland PC Hughes A, et al. Risk of suicidally in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880.
21. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997;58(suppl7):17-21.
22. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362
23. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997;58(suppl7):37-40.
24. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259-266
25. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Veaugh-Geiss A, Krebs EE, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008;31:851-865 (Pubitemid 351651555)
26. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitortreatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959-965
27. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009;23:493-509.
28. National Institute for Health and Clinical Excellence. Antenatal and postnatal mental health: clinical management and service guidance. 2007. (Clinical guideline 45.) http://guidance.nice.org.uk/CG45.
29. De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999;319:1106-1109 (Pubitemid 29494721)
30. De Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008;65:795-803.
31. Wright SK, Schroeter S. Hyponatremia as a complication of selective serotonin reuptake inhibitors. J Am Acad Nurse Pract 2008;20(1):4751.
32. Sharma H, Pompei P. Antidepressant-induced hyponatraemia in the aged. Avoidance and management strategies. Drugs Aging 1996;8:430-435 (Pubitemid 26163136)
33. Alvarez W, Jr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 2003;23(6):754-771.
34. Von Ruden AE, Adson DE, Kotlyar M. Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality./ Cardiovasc Pharmacol Ther 2008;13(1):32-40. (Pubitemid 351238293)
35. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute Ml or unstable angina. JAMA 2002;288:701-709 (Pubitemid 34848222)
36. Paykel ES. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol 2007;10:131-136